Interestingly, the authors also found that whereas unlabeled cetuximab (anti-EGFR mAb) inhibited ABY-029 binding in vitro, it had no effect on in vivo tumor contrast when injected 1 or 24 h before ABY-029. The gene discussed is EGFR; the disease is neoplasm.